Dicerna Pharmaceuticals (DRNA) PT Lowered to $20.00

Dicerna Pharmaceuticals (NASDAQ:DRNA) had its price target lowered by SunTrust Banks to $20.00 in a report published on Thursday morning, The Fly reports. SunTrust Banks currently has a buy rating on the biopharmaceutical company’s stock.

DRNA has been the topic of several other research reports. Zacks Investment Research downgraded shares of Dicerna Pharmaceuticals from a hold rating to a sell rating in a research note on Wednesday, May 15th. BidaskClub downgraded shares of Dicerna Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, April 16th. HC Wainwright restated a buy rating and issued a $22.00 price objective on shares of Dicerna Pharmaceuticals in a research note on Friday, May 3rd. ValuEngine downgraded shares of Dicerna Pharmaceuticals from a buy rating to a hold rating in a research note on Friday, April 26th. Finally, B. Riley raised their price objective on shares of Dicerna Pharmaceuticals from $21.00 to $24.00 and gave the stock a buy rating in a research note on Wednesday, March 13th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company’s stock. Dicerna Pharmaceuticals presently has an average rating of Buy and an average price target of $21.38.

Shares of DRNA stock opened at $12.10 on Thursday. Dicerna Pharmaceuticals has a 12 month low of $9.31 and a 12 month high of $17.98. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.31 and a current ratio of 5.00. The company has a market cap of $826.72 million, a price-to-earnings ratio of -10.08 and a beta of 2.30.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.16). Dicerna Pharmaceuticals had a negative net margin of 1,284.93% and a negative return on equity of 52.17%. The company had revenue of $3.11 million for the quarter, compared to analyst estimates of $10.59 million. On average, sell-side analysts anticipate that Dicerna Pharmaceuticals will post -1.23 earnings per share for the current fiscal year.

In other news, insider James B. Weissman sold 15,000 shares of the firm’s stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $15.00, for a total value of $225,000.00. Following the sale, the insider now owns 39,480 shares in the company, valued at $592,200. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 19.85% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. Quantamental Technologies LLC acquired a new stake in Dicerna Pharmaceuticals during the first quarter worth $26,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Dicerna Pharmaceuticals by 512.2% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,459 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 2,894 shares in the last quarter. Legal & General Group Plc boosted its stake in Dicerna Pharmaceuticals by 38.7% during the fourth quarter. Legal & General Group Plc now owns 9,186 shares of the biopharmaceutical company’s stock worth $98,000 after buying an additional 2,561 shares in the last quarter. Bank of America Corp DE boosted its stake in Dicerna Pharmaceuticals by 30.3% during the fourth quarter. Bank of America Corp DE now owns 10,596 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 2,465 shares in the last quarter. Finally, Jane Street Group LLC acquired a new stake in Dicerna Pharmaceuticals during the first quarter worth $153,000. Institutional investors and hedge funds own 86.16% of the company’s stock.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.

Recommended Story: Penny Stocks

The Fly

Analyst Recommendations for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.